E Weis1, T G Salopek2, J G McKinnon3, M P Larocque4, C Temple-Oberle3, T Cheng5, J McWhae3, R Sloboda4, M Shea-Budgell6. 1. Department of Ophthalmology and Visual Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB;; Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB; 2. Division of Dermatology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB; 3. Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB;; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB; 4. Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB; 5. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB; 6. Cancer Strategic Clinical Network, Alberta Health Services, Calgary, AB.
Abstract
INTRODUCTION: Survival in uveal melanoma has remained unchanged since the early 1970s. Because outcomes are highly related to the size of the tumour, timely and accurate diagnosis can increase the chance for cure. METHODS: A consensus-based guideline was developed to inform practitioners. PubMed was searched for publications related to this topic. Reference lists of key publications were hand-searched. The National Guidelines Clearinghouse and individual guideline organizations were searched for relevant guidelines. Consensus discussions by a group of content experts from medical, radiation, and surgical oncology were used to formulate the recommendations. RESULTS: Eighty-four publications, including five existing guidelines, formed the evidence base. SUMMARY: Key recommendations highlight that, for uveal melanoma and its indeterminate melanocytic lesions in the uveal tract, management is complex and requires experienced specialists with training in ophthalmologic oncology. Staging examinations include serum and radiologic investigations. Large lesions are still most often treated with enucleation, and yet radiotherapy is the most common treatment for tumours that qualify. Adjuvant therapy has yet to demonstrate efficacy in reducing the risk of metastasis, and no systemic therapy clearly improves outcomes in metastatic disease. Where available, enrolment in clinical trials is encouraged for patients with metastatic disease. Highly selected patients might benefit from surgical resection of liver metastases.
INTRODUCTION: Survival in uveal melanoma has remained unchanged since the early 1970s. Because outcomes are highly related to the size of the tumour, timely and accurate diagnosis can increase the chance for cure. METHODS: A consensus-based guideline was developed to inform practitioners. PubMed was searched for publications related to this topic. Reference lists of key publications were hand-searched. The National Guidelines Clearinghouse and individual guideline organizations were searched for relevant guidelines. Consensus discussions by a group of content experts from medical, radiation, and surgical oncology were used to formulate the recommendations. RESULTS: Eighty-four publications, including five existing guidelines, formed the evidence base. SUMMARY: Key recommendations highlight that, for uveal melanoma and its indeterminate melanocytic lesions in the uveal tract, management is complex and requires experienced specialists with training in ophthalmologic oncology. Staging examinations include serum and radiologic investigations. Large lesions are still most often treated with enucleation, and yet radiotherapy is the most common treatment for tumours that qualify. Adjuvant therapy has yet to demonstrate efficacy in reducing the risk of metastasis, and no systemic therapy clearly improves outcomes in metastatic disease. Where available, enrolment in clinical trials is encouraged for patients with metastatic disease. Highly selected patients might benefit from surgical resection of liver metastases.
Entities:
Keywords:
Uveal melanoma; choroidal melanoma; ciliary body melanoma; iris melanoma; melanoma; ocular melanoma; ophthalmology; practice guidelines
Authors: Lee M Jampol; Claudia S Moy; Timothy G Murray; Sandra M Reynolds; Daniel M Albert; Andrew P Schachat; Kenneth R Diddie; Robert E Engstrom; Paul T Finger; Kenneth R Hovland; Leonard Joffe; Karl R Olsen; Craig G Wells Journal: Ophthalmology Date: 2002-12 Impact factor: 12.079
Authors: D Gomez; C Wetherill; J Cheong; L Jones; E Marshall; B Damato; S E Coupland; P Ghaneh; G J Poston; H Z Malik; S W Fenwick Journal: J Surg Oncol Date: 2013-12-19 Impact factor: 3.454
Authors: Alexander Schmittel; Ronny Schuster; Nikolaos E Bechrakis; Jan M Siehl; Michael H Foerster; Eckhard Thiel; Ulrich Keilholz Journal: Melanoma Res Date: 2005-10 Impact factor: 3.599
Authors: Seppo Pyrhönen; Marjo Hahka-Kemppinen; Timo Muhonen; Väinämö Nikkanen; Sebastian Eskelin; Paula Summanen; Ahti Tarkkanen; Tero Kivelä Journal: Cancer Date: 2002-12-01 Impact factor: 6.860
Authors: S Leyvraz; S Piperno-Neumann; S Suciu; J F Baurain; M Zdzienicki; A Testori; E Marshall; M Scheulen; T Jouary; S Negrier; J B Vermorken; E Kaempgen; X Durando; D Schadendorf; R Karra Gurunath; U Keilholz Journal: Ann Oncol Date: 2014-02-07 Impact factor: 32.976